Combining Lumipulse pTau217 and Aβ42 as confirmatory tests for Aβ pathology prior to DMT
The general performance of the Lumipulse assays was similar across both the ADCC and ITTC, indicating strong repeatability independent of clinical stage. Focusing on only participants eligible for DMTs increased sensitivity and improved accuracy for the Aβ-containing pTau217/Aβ42 ratio and linear combination of markers, and resulted in small numbers of unclassified participants by the test.
Authors
- James D. Doecke (ORCID: https://orcid.org/0000-0003-2863-0293)
- John Winslow (ORCID: https://orcid.org/0000-0003-2701-2493)
- Ahmed Chenna (ORCID: https://orcid.org/0000-0001-6201-2494)
- Robert Martone (ORCID: https://orcid.org/0000-0001-7776-6109)
- C. Petropoulos
- Mintzu Lo
- Christopher C. Rowe
- Colin L Masters
- Ralph N Martins
- Christopher J Fowler
- Stephanie R Rainey‐Smith
- Brandon Yee
- Simon M. Laws
- Youssouf Badal
Institutions
- Edith Cowan University (AU)
- The University of Melbourne (AU)
- Murdoch University (AU)
- The University of Western Australia (AU)
- Florey Institute of Neuroscience and Mental Health (AU)
- LabCorp (United States) (US)
- IGM Biosciences (United States) (US)
- Australian e-Health Research Centre (AU)
- Australian Alzheimer’s Research Foundation (AU)
- Austin Health (AU)
- Macquarie University (AU)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_104702
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00